Successful conversion from thiazide to tolvaptan in a patient with stage D heart failure and chronic kidney disease before heart transplantation

International Heart Journal

Volumn 54, Issue 1, 2013, Pages 48-50

  Imamura, Teruhiko ^a   Kinugawa, Koichiro ^a   Kato, Naoko ^a   Minatsuki, Shun ^a   Muraoka, Hironori ^a   Inaba, Toshiro ^a   Maki, Hisataka ^a   Shiga, Taro ^a   Hatano, Masaru ^a   Yao, Atsushi ^a   Kyo, Shunei ^a   Ono, Minoru ^b   Komuro, Issei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Diuretics; Hyponatremia; Renal dysfunction

Indexed keywords

BILIRUBIN; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; CREATININE; CYCLOSPORIN; ENALAPRIL; FUROSEMIDE; INOTROPIC AGENT; SODIUM; SPIRONOLACTONE; TOLVAPTAN; TORASEMIDE; TRICHLORMETHIAZIDE;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHRONIC KIDNEY DISEASE; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS SURGERY; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; HEART EJECTION FRACTION; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RIGHT ATRIUM PRESSURE; HEART TRANSPLANTATION; HUMAN; HYPONATREMIA; ISCHEMIC CARDIOMYOPATHY; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; SODIUM BLOOD LEVEL; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SUBSTITUTION; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; HYPONATREMIA; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; RENAL AGENTS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TIME; TREATMENT OUTCOME; TRICHLORMETHIAZIDE;

EID: 84874351115     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.54.48     Document Type: Article

References (18)

1. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-10.
2. Douglas I. Hyponatremia: why it matters, how it presents, how we can manage it. Cleve Clin J Med 2006; 73 Suppl 3: S4-12. (Review)
3. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 1994; 128: 564-74. (Review)
4. Abdel-Qadir HM, Tu JV, Yun L, Austin PC, Newton GE, Lee DS. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J 2010; 160: 264-71.e1.
5. de Silva R, Nikitin NP, Witte KK, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J 2006; 27: 569-81.
6. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-235.
7. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report--2011. J Heart Lung Transplant 2011; 30: 1078-94.
8. Baran DA, Galin ID, Gass AL. Calcineurin inhibitor-associated early renal insuffi ciency in cardiac transplant recipients: risk factors and strategies for prevention and treatment. Am J Cardiovasc Drugs 2004; 4: 21-9. (Review)
9. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006; 97: 1759-64.
10. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007; 9: 1064-9.
11. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-112.
12. Imamura T, Kinugawa K, Shiga T, et al. Correction of hyponatremia by tolvaptan before left ventricular assist device implantation. Int Heart J 2012; 53: 391-3.
13. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. Am Coll Cardiol 2008; 52: 1540-5.
14. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-31.
15. Singh M, Shullo M, Kormos RL, et al. Impact of renal function before mechanical circulatory support on posttransplant renal outcomes. Ann Thorac Surg 2011; 91: 1348-54.
16. Imamura T, Kinugawa K, Shiga T, et al. Preoperative levels of bilirubin or creatinine adjusted by age can predict their reversibility after implantation of left ventricular assist device. Circ J. (in press)
17. Kwon TH, FrØkiaer J, Knepper MA, Nielsen S. Reduced AQP1, -2, and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass. Am J Physiol 1998; 275: F724-41.
18. Imamura T, Kinugawa K, Shiga T, et al. Novel criteria with urine osmolality effectively predict responses to tolvaptan in decompensated heart failure patients - An association between non-responders and chronic kidney disease. Circ J. (in press)